CXC-chemokine antagonists isolated from Rhipicephalus sanguineus
US7670802B2 · kind B2 · utility
0Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2006 |
| Grant date | Mar 2, 2010 |
| Priority date | — |
| Expiry date | Oct 30, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel CXC-chemokine binding protein is cloned from the salivary glands of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immuno-modulatory compounds and in the treatment or prevention of CXC-chemokine-related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.